CanSino expects a net profit of 27.87 million yuan in 2025, reversing losses year-on-year

NightAirdropper · 2026-02-26T11:19:00+00:00

CanSino's 2025 Performance Brief shows that the company achieved operating revenue of 1.068 billion yuan, a year-on-year increase of 26.18%; net profit attributable to shareholders was 27.87 million yuan, successfully turning losses into profits. The company has significantly improved its profitability through innovation and cost reduction and efficiency enhancement strategies.

NightAirdropper

2026-02-26 11:19:00

Abstract generation in progress

CanSino Biologics (688185) announced its 2025 performance forecast on the evening of February 26. The company is expected to achieve an operating revenue of 1.068 billion yuan in 2025, a year-on-year increase of 26.18%. The net profit attributable to shareholders is projected to be 27.87 million yuan, compared to a loss of 379 million yuan in the same period last year.

CanSino stated that during the reporting period, the company continued to implement a development strategy centered on innovation and focused on commercialization. The revenue of China’s first quadrivalent meningococcal conjugate vaccine, ManHeshin, maintained steady growth. Meanwhile, the company actively promoted cost reduction and efficiency improvements, effectively controlling various expenses; production and sales coordination was further optimized, and gross profit margin also increased. Overall, the company’s profitability significantly improved, successfully turning the net profit attributable to shareholders positive during the reporting period.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes